MPM Capital
Boston, Massachusettsmpmcapital.com
Overview
MPM Capital, also known as MPM BioImpact, is a world-leading biotechnology investment firm with nearly three decades of experience. The firm creates and invests in private and public companies across all stages of development that seek to translate scientific innovations into cures for major diseases, with a particular focus on biotechnology, life sciences, and oncology. MPM BioImpact combines the venture capital activities of MPM Capital with the impact and public equity investing of its affiliate, BioImpact Capital. The firm has been involved in the development of 60 FDA-approved drugs.
Portfolio Companies
21
Website
mpmcapital.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Umoja Biopharma | Jan 2025 | Series C | Co-investor |
| Aktis Oncology | Sep 2024 | Series B | Co-investor |
| Frontier Medicines | Feb 2024 | Series C | Co-investor |
| AstronauTx | Oct 2023 | Series A | Co-investor |
| ReCode Therapeutics | Sep 2023 | Series B Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
